文献速递妇科肿瘤

外观早期卵巢癌的前哨淋巴结活检:前瞻性多中心研究(SELLY)最终结果

Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY).
PubMed 文献 · Eur J Cancer · 2023-11-14

该多中心前瞻性II期研究于2018年3月至2022年7月在7个中心纳入174例疑似I-II期上皮性卵巢癌患者,比较前哨淋巴结示踪与系统性淋巴结清扫检测淋巴结转移的敏感性和特异性。99例(58.6%)成功定位至少1枚前哨淋巴结,其中15例(15.1%)淋巴结阳性;前哨淋巴结活检敏感性73.3%、特异性100.0%,4例(26.7%)淋巴结阳性患者前哨淋巴结阴性。

要点

  • 前哨淋巴结活检敏感性73.3%、特异性100.0%,未达预期敏感性。
  • 4例(26.7%)淋巴结阳性患者的前哨淋巴结为阴性。
  • 15例淋巴结阳性患者中7例(63.6%)需超分期方案才检出转移。

核心结论

  • 在外观早期上皮性卵巢癌中,前哨淋巴结定位未达到预期敏感性,1/4患者可能存在前哨淋巴结活检未识别的淋巴转移。
  • 35.0%的淋巴结阳性患者仅通过前哨淋巴结超分期方案被识别。

研究设计与样本

  • 多中心、前瞻性、II期试验,2018年3月至2022年7月在7个中心开展。
  • 纳入拟行手术分期的 presumed I-II 期上皮性卵巢癌患者。
  • 患者于骨盆漏斗韧带及可行时于子宫卵巢韧带注射吲哚菁绿,行前哨淋巴结活检后行盆腔及腹主动脉旁淋巴结清扫。
  • 所有淋巴结均行组织病理学检查,前哨淋巴结采用超分期方案。

主要发现

  • 174例入组,169例(97.1%)接受研究干预。
  • 99例(58.6%)成功定位至少1枚前哨淋巴结,其中15例(15.1%)淋巴结阳性。
  • 15例中11例(73.3%)前哨淋巴结正确识别病变;11例中7例(63.6%)需超分期方案检出淋巴结转移。
  • 4例(26.7%)淋巴结阳性患者前哨淋巴结阴性(敏感性73.3%、特异性100.0%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate the sensitivity and specificity of sentinel-lymph-node mapping compared with the gold standard of systematic lymphadenectomy in detecting lymph node metastasis in apparent early stage ovarian cancer. METHODS: Multicenter, prospective, phase II trial, conducted in seven centers from March 2018 to July 2022. Patients with presumed stage I-II epithelial ovarian cancer planned for surgical staging were eligible. Patients received injection of indocyanine green in the infundibulo-pelvic and, when feasible, utero-ovarian ligaments and sentinel lymph node biopsy followed by pelvic and para-aortic lymphadenectomy was performed. Histopathological examination of all nodes was performed including ultra-staging protocol for the sentinel lymph node. RESULTS: 174 patients were enrolled and 169 (97.1 %) received study interventions. 99 (58.6 %) patients had successful mapping of at least one sentinel lymph node and 15 (15.1 %) of them had positive nodes. Of these, 11 of 15 (73.3 %) had a correct identification of the disease in the sentinel lymph node; 7 of 11 (63.6 %) required ultra-staging protocol to detect nodal metastasis. Four (26.7 %) patients with node-positive disease had a negative sentinel-lymph-node (sensitivity 73.3 % and specificity 100.0 %). CONCLUSIONS: In a multicenter setting, identifying sentinel-lymph nodes in apparent early stage epithelial ovarian cancer did not reach the expected sensitivity: 1 of 4 patients might have metastatic lymphatic disease unrecognized by sentinel-lymph-node biopsy. Nevertheless, 35.0 % of node positive patients was identified only thanks to ultra-staging protocol on sentinel-lymph-nodes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Nero C, Bizzarri N, Di Berardino S, et al. Sentinel-node biopsy in apparent early stage ovarian cancer: final results of a prospective multicentre study (SELLY). Eur J Cancer. 2023. PMID: 38006759. doi:10.1016/j.ejca.2023.113435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。